Abstract:Rongce Zhao, 1, &ast Jing Zhou, 2, &ast Zehao Zheng, 1, &ast Xinhao Xiong, 1 Qiaoxuan Wang, 3 Shaohua Li, 1 Wei Wei, 1 Rongping Guo 1 1 Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; 2 Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China; 3 Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Rongping Guo; Wei Wei, Department of Liver Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, People's Republic of China, Email ; Background: For patients with large unresectable hepatocellular carcinoma (HCC), the effectiveness of conventional transarterial chemoembolization (TACE) remains suboptimal, which necessitates the administration of substantial volumes of chemotherapy drugs and lipiodol, thereby increasing the risk of liver failure and other chemotherapy-related complications. Therefore, we devised a strategy of initial hepatic arterial infusion chemotherapy (HAIC) followed by sequential drug-eluting bead TACE (DEB-TACE). In our treatment design, a lower tumor burden after HAIC facilitated complete embolization of tumor vasculature, and the use of less amount of embolic agents reduced the incidence of liver failure and embolization syndromes. Methods: This retrospective study evaluated consecutive patients with unresectable large HCC with a maximum tumor diameter of ≥ 7 cm who received FOLFOX-HAIC combined with sequential DEB-TACE from April 2019 to February 2024. Efficacy was evaluated using the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS); and safety was assessed using the frequency of key adverse events (AEs). Results: Among the 76 patients included, the median maximum tumor diameter was 12.4 cm (range, 7.0– 23.4 cm). The overall ORRs based on mRECIST and RECIST 1.1 criteria were 94.1% and 51.5%, respectively. The median OS was 28.1 months (95% CI, 22.7– 33.4), and the median PFS was 11.7 months (95% CI, 7.7– 15.8). All patients experienced AEs, but only 18.4% experienced grade 3 or 4 AEs, there was no treatment-related mortality. Conclusion: In this single-center, retrospective study, our results suggested that FOLFOX-HAIC with sequential DEB-TACE demonstrated promising efficacy and safety for patients with unresectable HCC with a maximum tumor diameter of ≥ 7 cm. Keywords: large unresectable hepatocellular carcinoma, hepatic arterial infusion chemotherapy, drug-eluting bead transarterial chemoembolization, sequential Hepatocellular carcinoma (HCC) is one of the most common malignant tumors and is the third leading cause of cancer-related deaths worldwide. 1 Approximately 80% of HCC cases worldwide are in developing countries, 2,3 where HCC surveillance is not widely applied. Consequently, most patients in these areas with the highest risk of HCC are initially diagnosed with large tumors. 4 However, most large HCC cases are not suitable candidates for surgical resection because of insufficient residual liver volume, insufficient surgical margins, or macrovascular invasion. 5 The Barcelona Clinic Liver Cancer (BCLC) guidelines advocate the use of transarterial chemoembolization (TACE) as a therapeutic strategy for patients with unresectable HCC. 6 However, the effectiveness of TACE is often suboptimal in patients with large HCC tumors, 7,8 which have abundant extrahepatic collateral arteries, making it difficult to perform complete embolization. In addition, the use of a large amount of embolization agents may cause serious adverse events (SAEs), such as hepatic dysfunction, postembolization syndrome, and ectopic embolization. 9,10 Hepatic arterial infusion chemotherapy (HAIC) exerts its antitumor effect through the continuous infusion of high concentrations of chemotherapeutic agents. 11 In recent years, several studies have demonstrated that HAIC with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX) significantly improved the survival of patients with advanced HCC. 12–14 Li et al report -Abstract Truncated-

Oxaliplatin and 5-Fluorouracil Hepatic Infusion with Lipiodolized Chemoembolization in Large Hepatocellular Carcinoma.

FOLFOX-Based Hepatic Arterial Infusion Chemotherapy with Sequential Drug-Eluting Bead Transarterial Chemoembolization for Unresectable Large Hepatocellular Carcinoma: A Single-Center Retrospective Cohort Study

Comparison Between Chemoembolization Combined with Radiotherapy and Chemoembolization Alone for Large Hepatocellular Carcinoma

Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma

Efficacy and Safety of Transarterial Chemoembolization with a Three-Stage Mixed Chemoembolic Regimen for Large Unresectable Hepatocellular Carcinoma.

Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy Combined a Tyrosine Kinase Inhibitor for Treatment of Large Hepatocellular Carcinoma

Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma

Transarterial Chemoembolization for Huge Hepatocellular Carcinoma with Diameter over Ten Centimeters: a Large Cohort Study

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial

The Long-Term Efficacy of Combined Chemoembolization and Local Irradiation in the Treatment of Patients with Large Hepatocellular Carcinoma.

Preliminary Clinical Study of Transcatheter Arterial Chemoembolization with ContourSe Microspheres and Lipiodol in Patients with Large Hepatocellular Carcinoma

Transarterial Chemoembolization Combined with Lenvatinib Plus Sequential Microwave Ablation for Large Hepatocellular Carcinoma Beyond Up-to-Seven Criteria: A Retrospective Cohort Study

TACE Combined with Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin, 5-Fluorouracil and Folinic Acid for Intermediate and Advanced Hepatocellular Carcinomas

Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): Multicenter retrospective study

Exploratory Study of Microparticle Transcatheter Arterial Chemoembolization Combined with Resection for Huge Hepatocellular Carcinoma

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma

Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma

Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: A prospective study.